About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials in Tennessee | 519 Studies

Clinical Trials LymphomaTennessee

Lymphoma Clinical Trials in Tennessee

Find 519 clinical trials for lymphoma near Tennessee. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Tennessee

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 1-20 of 519 trials

TerminatedAn Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib StudyThis is a long-term safety extension study of idelalisib (GS-1101; CAL-101) in patients with hematologic malignancies who complete other idelalisib studies.NCT01090414·Huntsville, Alabama and 17 others RecruitingCAR T-cell Long-Term Follow-Up, Quality of Life and Adverse ReactionsTo learn more about the long-term health in patients treated for B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Cluster of Differentiation antigen 19 (CD19) -redirected…NCT07048535·Memphis, Tennessee

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

TerminatedTreatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate MofetilRATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the…NCT00608517·Nashville, Tennessee and 3 others

CompletedStudy of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)The purpose of this study is to compare lenalidomide to a control drug and see which one delays Diffuse Large B-Cell Lymphoma (DLBCL) disease progression longer.NCT01197560·Burbank, California and 56 others

TerminatedInotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic LeukemiaThis trial is a limited multi-center, Phase II study to evaluate inotuzumab ozogamicin (Besponsa) in pediatric patients with MRD positive CD22-positive B-lymphoblastic leukemia…NCT03913559·San Diego, California and 1 other

CompletedA Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin LymphomaThe purpose of this study is to identify if, and at what dose, ibrutinib may be administered with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)…NCT01569750·New York, New York and 6 others

CompletedBendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaA phase II trial to evaluate the efficacy and safety of combination bendamustine and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.NCT00831597·Beverly Hills, California and 32 others

CompletedS0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell LymphomaRATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.NCT00376961·Anchorage, Alaska and 146 others

CompletedStudy of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT StudyThe primary objective of the study is to compare the complete response (CR) rate of bendamustine and rituximab (BR) with that of standard treatment regimens of either rituximab…NCT00877006·Tucson, Arizona and 127 others

TerminatedStudy of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)This is an open-label, multicentre study to characterize the safety and preliminary efficacy of the human anti CD19 antibody MOR00208 in adult subjects with relapsed/refractory…NCT01685021·Columbus, Ohio and 2 others

CompletedCyclophosphamide and Filgrastim in Treating Patients With Stage IV, Relapsed, or Refractory Low-Grade Follicular Non-Hodgkin's LymphomaRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.NCT00002501·Chicago, Illinois and 14 others

TerminatedStudy of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)This study has 3 parts.NCT01925612·Phoenix, Arizona and 50 others

RecruitingThis is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin LymphomaThis study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and evaluate the…NCT07121946·Duarte, California and 5 others

CompletedTC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic LeukemiaTC-110 T cells are a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human CD19, fused to the…NCT04323657·Denver, Colorado and 2 others

RecruitingTAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerThe purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to…NCT02693535·Birmingham, Alabama and 180 others

Active not recruitingProvision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior TransplantationThis study seeks to examine treatment therapy that will reduced regimen-related toxicity and relapse while promoting rapid immune reconstitution with limited serious…NCT02790515·Memphis, Tennessee

CompletedStudy of the Glutaminase Inhibitor CB-839 in Hematological TumorsMany tumor cells, in contrast to normal cells, have been shown to require the amino acid glutamine to produce energy for growth and survival.NCT02071888·Scottsdale, Arizona and 6 others

CompletedA Safety and Tolerability Study of INCAGN02385 in Select Advanced MalignanciesThe purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.NCT03538028·Los Angeles, California and 3 others

TerminatedT Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell TransplantRATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors predict whether patients undergoing donor stem cell transplant will develop acute…NCT00651716·Nashville, Tennessee

CompletedA Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic CancersThis is a study of CDX-1127, a therapy that targets the immune system and may act to promote anti-cancer effects.NCT01460134·Scottsdale, Arizona and 9 others

Page 1 of 26Next

Other Conditions in Tennessee

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia